



HERANTIS
PHARMA

Toward clinical breakthroughs based on leading science

Danske Bank Small & Mid Cap Day

LSX Nordic

Pareto Securities 11th Healthcare Conference

1-3 September 2020

Disclaimer

By accepting to receive this presentation from Herantis Pharma Plc (the "Company"), you agree to be bound by the following conditions.

This presentation and any oral communication in connection with it (the "Information") are strictly confidential and are being provided to you solely for your information. This presentation may not be retained by you and the Information may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose.

The Information does not constitute, and should not be construed as, an offer to sell or issue or solicitation of an offer to buy or subscribe for securities anywhere in the world or an inducement to enter into investment activity.

No part of the Information should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. The Information does not constitute investment, legal, accounting, regulatory, taxation or other advice and the Information does not take into account investment objectives or legal, accounting, regulatory, taxation or financial situation or particular needs that you may have. The Information shall not be construed as comprising an investment recommendation in respect of any securities. You are solely responsible for forming your own opinions and conclusions and for making your own independent assessment of the Information and for seeking adequate independent professional advice.

The Information has been prepared by the Company and has not been independently verified and no representation or warranty, express or implied, is made or given by or on behalf of the Company or Carnegie Investment Bank AB (publ) ("Carnegie"), or any of their respective members, directors, officers or employees or any other person as to, and no reliance should be placed upon, the accuracy, completeness or fairness of the Information or opinions contained in the Information. None of the Company or Carnegie or any of their respective members, directors, officers or employees or any other person accepts any liability whatsoever for any loss howsoever arising from any use of the Information or otherwise arising in connection therewith.



The Information may include forward-looking statements. The words "believe," "expect," "anticipate," "intend," "may," "plan," "estimate," "will," "should," "could," "aim," "target," "might," or, in each case, their negative, or similar expressions identify certain of these forward-looking statements. Others can be identified from the context in which the statements are made. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the Company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future, involve elements of subjective judgment and analysis and are based upon the best judgment of the Company as at the date of this presentation.

The Information is provided as at the date of this presentation and is subject to change without notice.

High Impact Science In High Impact Diseases

- Highly differentiated assets with novel and distinct scientific approaches
- Targeting unique therapeutic opportunities in despairing diseases
- Potentially disease-modifying and curative in their current indications, and beyond
 - **CDNF (Cerebral Dopamine Neurotrophic Factor) biologic for Parkinson disease**
 - **Lymfactin® VEGF-C gene therapy for secondary Lymphedema**
- Both assets safely into humans, in clinical proof of concept studies, funded to data readouts

World class research published in Nature and Science



CDNF For Parkinsons Disease (PD)

- PD an incurable brain disease caused by degeneration of dopaminergic neurons in midbrain
 - CDFN a natural protein acts in several ways to potentially modify the diseases process
 - Massive medical need with 7-10 million patients worldwide, societal costs \$25bn US alone
- **Highly promising preclinical & early clinical data confirms safety, suggests biological activity and potential slowing of disease progression**
- Phase I-II completed successfully Aug 2020





Lymfactin® For Lymphedema (LE)

- LE is severe chronic swelling and accumulation of lymph due to damaged lymph drainage
 - Lymfactin® is a local gene therapy, which stimulates natural growth of lymphatic vessels
 - Huge medical need with over 140 million patients worldwide
- Lymfactin® is targeted as the first **curative** treatment of secondary BCAL Lymphedema by reconstituting the lymphatic system
- Phase I completed, Phase II ongoing with read-out expected Q1/2021




How Our Drugs Work

- **CDNF biologic therapy** is dosed directly into the brain where it promotes functional **recovery** of dopaminergic **neurons** in the putamen, and protects the dopaminergic cell bodies in the substantia nigra
- **Lymfactin® VEGF-C gene therapy** is administered locally into the armpit together with lymph node transfer surgery as a single-dose treatment where it promotes **reconstitution** of a functional **lymphatic** system



Rich Pipeline Progressing Towards Significant Markets



CDNF Strong Safety Data And Promising Efficacy Potential

- **Successful FIH Study Just Completed August 2020**

- **Primary objective to establish safety**

Data confirms CDFN safe and well tolerated

- **Secondary objective to explore efficacy indicators**

Data varied but suggests potential slowing of disease progression in some patients, as well potential signals of biological activity in some patients (PET DAT)

Promising data in FIH study where safety is focus, patients have advanced disease, most dopaminergic neurons are lost, CDFN doses are low, and observed improvements in efficacy scores not powered for statistical evaluation


Study results to be presented via company webinar on 15th September
– please consult www.herantis.com

“In addition to the study’s favourable safety profile, it is encouraging to observe an improvement in the UPDRS motor score as well as an indication of a biological response compared to baseline, which may be clinically relevant. In chronic diseases, such as Parkinson’s, where patients continue to decline over time despite receiving treatment, the differences observed in this study present a potential opportunity for the development of meaningful therapeutic effects.”

- Prof Per Svenningsson, Karolinska University Hospital (Study PI)

CDNF Results Compelling Platform For Next Gen xCDNF

- **Common challenge in CNS diseases is drug delivery to the brain**
 - CDNF currently administered via surgically implanted device
- **xCDNF, i.e. smaller selected fragments of CDNF**
 - retain the biological activity of CDNF (comparable efficacy in PD models; same target!)
 - penetrate the BBB → administered subcutaneously no need for medical device
 - highly potent molecules
- **xCDNF optimisation at final stages of compound selection to take forward for development**



Lymfactin Established Safe, Phase II Underway

- **Phase I study completed 2019 (follow-up continues until 2023)**
 - Data confirms Lymfactin® safe and well tolerated by patients
 - Promising improvements observed in signs and symptoms of LE after 12-month follow-up (uncontrolled data)
- **Randomized Phase II study ongoing**
 - Results expected Q1 2021

Journal of Plastic, Reconstructive & Aesthetic Surgery (2020) 73, 1612-1621



ELSEVIER




JPRAS
An International Journal of
Surgical Reconstruction
www.JPRASurg.com

Phase 1 Lymfactin® Study: Short-term Safety of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema

Pauliina Hartiala^{a,*}, Sinikka Suominen^b, Erkki Suominen^a,
Ilkka Kaartinen^c, Juha Kiiiski^d, Tiina Viitanen^a, Kari Alitalo^e,
Anne M Saarikko^{b,**}

^aDepartment of Plastic and General Surgery, Turku University Hospital and University of Turku, Turku, Finland
^bDepartment of Plastic Surgery, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland
^cDepartment of Reconstructive Plastic Surgery, Karolinska University Hospital, Stockholm, Sweden
^dDepartment of Plastic Surgery, Tampere University Hospital and University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland
^eWihuri Research Institute and Translational Cancer Medicine Program, Biomedicum Helsinki, University




“Breast cancer-associated lymphedema is a highly debilitating disease that severely impacts quality-of-life of patients that have already experienced a significant impact on their day-to-day health. Addressing this unmet medical need is an important endeavor to which we are excited to contribute. Lymfactin® has very interesting product profile addressing underlying root cause by restoring functionality of lymphatic vasculature, which will be critical to evaluate going forward.”

- Associate Professor Anne Saarikko of Hospital of Helsinki (Study PI)

Herantis Proposition Summary

- Groundbreaking science at leading edge of biological and gene therapy innovation
- Potential to impact significant diseases that have shown limited progress in decades
- Confirmed successful translation from discovery into humans
- Highly skilled team who know what is needed, and how to do it
- Clear path to potential partnerability and commercialization



A woman in a white lab coat is shown from the chest up, looking upwards and to the right. Her right arm is raised, and she appears to be holding a long, thin object, possibly a pipette or a test tube. The entire image is overlaid with a semi-transparent blue filter. The text 'Thank You' is centered in the middle of the image in a white, sans-serif font.

Thank You